Purpose
|
Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. Axitinib is marketed under the name Inlyta?, and if one previous systemic therapy for kidney cell cancer has failed, axitinib is indicated.
|
Characteristics
|
Tradename: AG 013736 Source of Compound: synthetic Target: c-Kit inhibitor, PDGFR inhibitor, VEGFR inhibitor Receptor: c-Kit,PDGFRβ,VEGFR1, VEGFR2, VEGFR3 Status: USP,CP,
|
Purification
|
All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality.
|
Purity
|
99?%
|
Formula
|
C22H18N4OS
|
Solubility
|
Soluble in DMSO
|